Together, these results indicated the potential synergy of the BBR and gefinitib combination on the growth, migration, invasion inhibition and enhanced cell death in NSCLC including the EGFR‐TKI–resistant lung cancer cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.